Secretome of Dermal Fibroblasts Spheroids
| Basic Research | Non- clinical | Phase 1 | Phase 2 | Phase 3 | Approval |
|---|---|---|---|---|---|
Active ingredients in the process of wound-healing such as ENA-78, bFGF, G-CSF, GM-CSF, GROα, IL-6, IL8, MCP-1, RANTES, Serpin E1, μPAR, and VEGF, are included.
CF-FECS-DF
Media
| 1 | Angiogenin |
|---|---|
| 2 | CHI3L1, YKL-40 |
| 3 | DPPIV |
| 4 | EGF |
| 5 | ENA-78 |
| 6 | bFGF |
| 7 | G-CSF |
| 8 | GM-CSF |
| 9 | CXCL1 / CROα |
| 10 | HGF |
| 11 | IL-6 |
| 12 | IL-8 |
| 13 | CCL2 / MCP-1 |
| 14 | MIF |
| 15 | Pentraxin3 / TSF-14 |
| 16 | CCL5 / RANTES |
| 17 | Serpin E1 |
| 18 | μPAR |
| 19 | VEGF |
| 1 | Angiogenin |
|---|---|
| 2 | CHI3L1, YKL-40 |
| 3 | DPPIV |
| 4 | EGF |
| 5 | ENA-78 |
| 6 | bFGF |
| 7 | G-CSF |
| 8 | GM-CSF |
| 9 | CXCL1 / CROα |
| 10 | HGF |
| 11 | IL-6 |
|---|---|
| 12 | IL-8 |
| 13 | CCL2 / MCP-1 |
| 14 | MIF |
| 15 | Pentraxin3 / TSF-14 |
| 16 | CCL5 / RANTES |
| 17 | Serpin E1 |
| 18 | μPAR |
| 19 | VEGF |
The fibroblast proliferation was promoted more when CF-FECS-DF was treated than when the secretome of 2D fibroblasts was treated on fibroblasts.
It recovers the site where fibroblasts are lost by promoting the proliferation and activity of fibroblasts.
| Media | 2D fibroblast | CF-FECS-DF | |
|---|---|---|---|
| Day 0 |  |
 |
 |
| Day 1 |  |
 |
 |
| Day 2 |  |
 |
 |
| Day 3 |  |
 |
 |
| Day 4 |  |
 |
 |
Loss Site
When treating CF-FECS-DF on vascular endothelial cells (HUVEC), more active angiogenesis was induced than when treating an angiogenesis promoter. Angiogenesis helps to heal wounds as it is involved in the formation of new tissues and supplies nutrients and oxygen to growing tissues.
Media 
|
Boost (bFGF) 
|
CF-FECS-DF 
|
|
